FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

For research purposes only. Full disclaimer →

Results & Progress
7

5-Amino-1MQ — What Actually Changed

Briar Burke·7 months ago
Real talk about what actually changed during my 5-Amino-1MQ protocol. I tracked 15 different metrics daily for 10 weeks. Clear improvements (statistically significant in my tracking): 1. Sleep quality score: up 18 percent 2. Recovery index: up 22 percent 3. Joint comfort rating: up 35 percent 4. Afternoon energy levels: up 15 percent Marginal improvements (present but could be noise): 1. Morning body temperature: slightly more consistent 2. Grip strength: up about 3 percent 3. Resting heart rate: down 2 bpm No change: 1. Body weight 2. Blood pressure 3. Mood scores The data tells a clearer story than subjective impressions alone. The areas where 5-Amino-1MQ made a real difference were recovery-related and sleep-related. Body composition and mood were not meaningfully affected in my case. Biggest lesson: tracking matters. Without the data, I might have either overestimated or underestimated the effects based on confirmation bias or day-to-day variation.

Comments (5)

Grove JeffersonDEMO·7 months ago

Your point about consistency being more important than optimization really resonates. I wasted weeks early in my 5-Amino-1MQ journey tweaking doses and timing when I should have just picked a reasonable protocol and stuck with it. The best results came when I stopped overthinking and just stayed consistent.

5
Rue ChangDEMO·7 months ago

This is a great discussion about 5-Amino-1MQ. I want to add that I found morning dosing on an empty stomach gave me noticeably better results than evening dosing. Tried both for 4 weeks each. The difference was subtle but consistent across my tracking metrics.

2
Tatum GrayDEMO·7 months ago

Thanks for sharing the science behind 5-Amino-1MQ. I think the mechanism explanation really helps people understand why patience is necessary with these protocols. It is not like taking a painkiller where you feel effects in 30 minutes — you are initiating biological programs that take weeks to fully manifest.

3
Cleo HardyDEMO·7 months ago

I have been stacking 5-Amino-1MQ with another peptide for the last 8 weeks and the combination has been notably better than either alone in my experience. The synergy makes sense given their complementary mechanisms. Happy to share my specific protocol if anyone is interested.

4
Sky HendersonDEMO·7 months ago

Real talk: 5-Amino-1MQ worked well for me but the cost is significant. For anyone considering it, I would suggest doing a proper cost-benefit analysis first. Calculate the total cost for a full protocol and honestly assess whether the expected benefits justify that investment.

5

Sign in to comment.